ATE240303T1 - 1,2,4-triazol-3-thion verbindungen - Google Patents

1,2,4-triazol-3-thion verbindungen

Info

Publication number
ATE240303T1
ATE240303T1 AT99946526T AT99946526T ATE240303T1 AT E240303 T1 ATE240303 T1 AT E240303T1 AT 99946526 T AT99946526 T AT 99946526T AT 99946526 T AT99946526 T AT 99946526T AT E240303 T1 ATE240303 T1 AT E240303T1
Authority
AT
Austria
Prior art keywords
triazole
thione compounds
thione
compounds
therapy
Prior art date
Application number
AT99946526T
Other languages
English (en)
Inventor
Andrew Baxter
Colin Bennion
Peter Cage
Nicholas Kindon
Michael Mortimore
Bryan Roberts
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE240303T1 publication Critical patent/ATE240303T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AT99946526T 1998-09-01 1999-08-27 1,2,4-triazol-3-thion verbindungen ATE240303T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802937A SE9802937D0 (sv) 1998-09-01 1998-09-01 Novel compounds
PCT/SE1999/001469 WO2000012489A1 (en) 1998-09-01 1999-08-27 1, 2, 4-triazole-3-thione compounds

Publications (1)

Publication Number Publication Date
ATE240303T1 true ATE240303T1 (de) 2003-05-15

Family

ID=20412435

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99946526T ATE240303T1 (de) 1998-09-01 1999-08-27 1,2,4-triazol-3-thion verbindungen

Country Status (8)

Country Link
US (1) US20020086862A1 (de)
EP (1) EP1109790B1 (de)
JP (1) JP2002525281A (de)
AT (1) ATE240303T1 (de)
AU (1) AU5892399A (de)
DE (1) DE69907926T2 (de)
SE (1) SE9802937D0 (de)
WO (1) WO2000012489A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2361003A (en) * 2000-04-07 2001-10-10 Astrazeneca Ab Novel compounds
AU2001273497A1 (en) * 2000-07-18 2002-01-30 Smithkline Beecham Corporation Use of IL-8 receptor antagonists in the treatment of virus infections
AU2003215549A1 (en) * 2003-02-03 2004-08-30 Janssen Pharmaceutica N.V. Mercaptoimidazoles as ccr2 receptor antagonists
US7276050B2 (en) * 2004-03-02 2007-10-02 Alan Franklin Trans-scleral drug delivery method and apparatus
WO2005097112A2 (en) * 2004-03-08 2005-10-20 Wyeth Ion channel modulators
JP2008509201A (ja) * 2004-08-11 2008-03-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃｃｒ２受容体アンタゴニストとしてのメルカプトイミダゾール
WO2006103119A2 (en) * 2005-04-01 2006-10-05 Galderma Research & Development Tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics
FR2883875A1 (fr) * 2005-04-01 2006-10-06 Galderma Res & Dev Nouveaux inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
JP2011506543A (ja) * 2007-12-19 2011-03-03 ビーエーエスエフ ソシエタス・ヨーロピア アゾリルメチルオキシラン、その使用及びそれを含む薬剤
BRPI0821362A2 (pt) * 2007-12-19 2014-10-14 Basf Se Composto, uso do mesmo, composição, semente, método para controlar fungos fitopatogênicos, medicamento, e, processos para preparar um antimicótico e para preparar compostos
EP2234488A2 (de) * 2007-12-19 2010-10-06 Basf Se Azolylmethyloxirane, ihre verwendung sowie sie enthaltende mittel
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
MX376108B (es) * 2012-12-20 2025-03-07 Tempest Therapeutics Inc Compuestos de triazolona y usos de los mismos.
CN103012233B (zh) * 2012-12-26 2015-08-26 华润赛科药业有限责任公司 一种n-(氨基硫代甲基)-5-氧代-1-丙基-2-吡咯烷乙酰胺的制备方法
AU2014315151A1 (en) 2013-09-06 2016-03-03 Inception 2, Inc. Triazolone compounds and uses thereof
WO2024223907A1 (en) * 2023-04-26 2024-10-31 Universitat De Barcelona 1,2,4-triazole-3-thione inhibitors of trex2 for use in the treatment of psoriasis, atopic dermatitis or ichthyosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators

Also Published As

Publication number Publication date
WO2000012489A1 (en) 2000-03-09
DE69907926T2 (de) 2004-02-19
EP1109790A1 (de) 2001-06-27
DE69907926D1 (de) 2003-06-18
AU5892399A (en) 2000-03-21
SE9802937D0 (sv) 1998-09-01
US20020086862A1 (en) 2002-07-04
JP2002525281A (ja) 2002-08-13
EP1109790B1 (de) 2003-05-14

Similar Documents

Publication Publication Date Title
DE69905170D1 (en) Thiazolopyrimidinderivate
SE9704546D0 (sv) Novel compounds
TR200100054T2 (tr) Paroksetin metansülfonat
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
EE200000320A (et) Uudsed ühendid
SE9704544D0 (sv) Novel compounds
DE69907926D1 (de) 1,2,4-triazol-3-thion verbindungen
YU13301A (sh) Muskarinski agonisti i antagonisti
HRP20020330B1 (de)
TR200000152T2 (tr) Yeni bileşikler.
IL101358A0 (en) Crystalline tiagabine hydrochloride monohydrate,its preparation and pharmaceutical compositions containing it
DE60003943D1 (de) Trimegestone enthaltende pharmazeutische zusammensetzungen
DE69943239D1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
AP2001002369A0 (en) Pharmaceutical complex.
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
IT1290910B1 (it) 2-amminotetralina otticamente attiva, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono, attive
EP1011329A4 (de) 7-methylthiooxomethyl- und 7-methylthiodioxomethyl-paclitaxele
MXPA04005226A (es) 1,3-diarilprop-2-en-1-onas, composiciones que las contienen y su utilizacion.
YU26001A (sh) Derivati ureidopiperidina kao selektivni antagonisti ljudskih nk3 receptora
ATE272651T1 (de) Verbindungen mit wachstumshormon-freisetzender eigenschaft
TWI231815B (en) Glycopeptide derivatives and pharmaceutical compositions containing the same for use as antibacterial agents
ATE382363T1 (de) Pharmazeutische zusammensetzung enthaltend bulbophyllum
ZA986139B (en) Sulphonamide compounds, processes for their preparation, pharmaceutical compositions containing the same and their use in therapy.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties